CRANBURY, NJ – August 11, 2016 – Solco Healthcare U.S. is proud to announce that the U.S. Food and Drug Administration (FDA) approved its generic equivalent of Vfend ® Tablets (Voriconazole Tablets), 50 mg and 200 mg. The Company is preparing for the commercialization of this product and expects to launch the product soon.

“We are pleased to receive FDA approval of generic voriconazole tablets, a product that was developed by our parent company, Prinston Pharmaceutical and manufactured in our Linhai, China facility,” said Hai Wang, President of Solco. “This is our fourth Abbreviated New Drug Applications (ANDA) approval in 2016, as we continue to strengthen our presence within the US generic market by providing high quality medicines at affordable prices.”

According to IMS Health (NSP), U.S. brand and generic sales of voriconazole tablets products were approximately $89.4 million for the 12 months ending in June 2016.

About Solco Healthcare U.S. Solco Healthcare U.S., headquartered in Cranbury, New Jersey, is an industry leader in marketing and distributing generic pharmaceuticals. Solco is committed to providing our customers with high quality, cost effective and innovative generic prescription medications. Solco offers a broad range of generic prescription products in many therapeutic categories, including differentiated, specialty drug products.

Solco is a fully owned subsidiary of Prinston Pharmaceutical Inc. Together we strive to offer greater access to affordable medications that you can trust.


Contacts: Chris Keith, Senior Vice President, Marketing & Business Development 
Phone: (609) 451-1000